arrow
M

Marco Sanduzzi-Zamparelli

bclc group and institut d'investigacions biomediques august pi i sunyer
H指数:18
被引数:1,133

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)

临床试验:二线治疗中,在瑞戈非尼基础上早期加用纳武利尤单抗治疗肝细胞癌患者(GOING试验)

2026-02-230
OAAI
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update

用于预后预测和治疗建议的BCLC策略: 2025更新

2025-10-270
PRE
Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy

突破接受免疫治疗晚期HCC患者进入重症监护的障碍

2025-08-120
OAAI
Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association

肝癌患者系统性治疗可及性差异:国际肝病肿瘤协会的分析

2025-07-310
PREAI
Corrigendum to” Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes,” [Eur J Cancer 2025 May 15:221:115404.]

勘误:“接受免疫治疗的肝细胞癌患者的心血管不良事件:合并症和临床结局的影响”,[Eur J Cancer 2025 May 15:221:115404.]

2025-06-120
PRE
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes

接受免疫治疗的原发性肝癌患者的心脏不良事件:合并症和临床结局的影响

2025-05-010
PRE
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study

肝癌患者合并SARS-CoV-2感染的结局: 一项国际性、多中心、队列研究

2022-06-2310
OAAI
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules
2022-04-0121
PRE
Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study

索拉非尼治疗肝移植术后复发性肝癌的回顾性研究

2021-09-1626
PREAI
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs

索拉非尼早期腹泻作为考虑向二线药物早期迁移的标志

2021-07-061
OAAI